![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, September 11, 2020 3:00:21 PM
They have to rule out / reduce , the role of chance.
So far we have data on 21 ? in an open label trial that's very encouraging BUT its not enough to say with 99% certainty ( P value .01 ) that we would see the same results with the next 21 patients.
They also need data on who RLF-100 works best on and best time to prescribe ( my guess is soon as a hospitalized patient needs O2 support....ie BEFORE going on a Vent )
If RLF-100 is a good as we hope it is then the FDA will want this in as many hospitals asap ....as long as they are confident in the trial data .
What I would like to see is a notice that the trial is fully enrolled ...then we can count down to read out.
By the way there are trials that could have been stopped at an Interim analysis ...but the DMC and Co decided to run to full completion to get the most detailed results ( and best stat sig reading ) possible ...Amarins Reduce It trial being the one I'm most familiar with
Kiwi
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM